Understanding and treating the heterogeneity of triple-negative breast cancer

Understanding and treating the heterogeneity of triple-negative breast cancer

EMJ

3 years
382 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Triple-negative breast cancer (TNBC) represents a biologically and clinically heterogeneous disease. At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Martine Piccart-Gebhart, MD, PhD, from Jules Bordet Institute, Brussels, Belgium, discusses the role of chemotherapy; targeted therapies, including anti-VEGF monoclonal antibody bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors; and immunotherapy for the treatment of patients with TNBC. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
869 Views
EMJ 3 years
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
2 Views
EMJ 3 years
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
6 Views
EMJ 3 years
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Category: Acute Lymphoblastic Leukemia
595 Views
EMJ 3 years
Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice
Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice
Category: Acute Lymphoblastic Leukemia
933 Views
EMJ 3 years
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
Category: Acute Lymphoblastic Leukemia
539 Views
EMJ 3 years
Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer
Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer
Category: Acute Lymphoblastic Leukemia
594 Views
EMJ 3 years
Addressing inequalities and unmet needs in breast cancer patients
Addressing inequalities and unmet needs in breast cancer patients
Category: Acute Lymphoblastic Leukemia
500 Views
EMJ 3 years
Breast cancer in Europe: Epidemiology and improving outcomes
Breast cancer in Europe: Epidemiology and improving outcomes
Category: Acute Lymphoblastic Leukemia
431 Views
EMJ 3 years
2005–2015 global analysis of advanced breast cancer
2005–2015 global analysis of advanced breast cancer
Category: Acute Lymphoblastic Leukemia
517 Views
EMJ 3 years